AUTL at a glance
Autolus Therapeutics plc (AUTL, SEC CIK 1730463) filed an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 16 institutional investment managers tracked by SignalX reported holding Autolus Therapeutics plc (AUTL) shares worth $49.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Piccina Cintia on September 2, 2026 of 6,713 shares at $2.34 per share.
- In the last 90 days, AUTL insiders reported 0 open-market purchases ($0) and 1 open-market sale ($16K) on Form 4, a net sale of $16K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$16K
- 13F holders
- 16 funds
- $49.6M · +1 vs prior quarter
SignalX for AUTL
Don't miss the next AUTL filing
- Alerts as it files. A push when AUTL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AUTL, by share count.
- Ask anything. An AI agent that reads every AUTL filing and answers with sources.
AUTL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Piccina Cintia | Sell | Sep 2, 2026 | 6,713 | $2.34 |
| Piccina Cintia | M | Sep 1, 2026 | 20,000 | $2.35 |
| Piccina Cintia | M | Sep 1, 2026 | 20,000 | - |
| BONNEY MICHAEL W | A | Jun 29, 2026 | 31,667 | - |
| YOUNG WILLIAM D | A | Jun 29, 2026 | 47,500 | - |
| Azelby Robert | A | Jun 29, 2026 | 31,667 | - |
| YOUNG WILLIAM D | A | Jun 29, 2026 | 31,667 | - |
| Leiderman Elisabeth | A | Jun 29, 2026 | 31,667 | - |
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AUTL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 16 | $49.6M |
| Q1 2026 | 15 | $41.8M |
| Q4 2025 | 13 | $67.4M |
| Q3 2025 | 15 | $68.6M |
| Q2 2025 | 18 | $91.5M |
| Q1 2025 | 16 | $58.8M |
| Q4 2024 | 13 | $100.1M |
| Q3 2024 | 14 | $95.5M |
- Millennium Management+1.02M (+498%)
- Morgan Stanley+319.0K (+34%)
- Citadel Advisors LLC+236.5K (+51%)
- BlackRock+122.7K (+8%)
- Invesco Ltd+13.3K (+25%)
- Marex Group plc−525.0K (-97%)
- Renaissance Technologies LLC−314.8K (-14%)
- Bank of America Corp−239.6K (-13%)
- JPMorgan Chase & Co−22.2K (-2%)
- Goldman Sachs Group−2.9K (-2%)
- StoneX Group Inc.+17.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 120 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
AUTL SEC filings: frequently asked questions
Are AUTL insiders buying or selling?
In the last 90 days, Autolus Therapeutics plc (AUTL) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $15,682 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AUTL stock?
As of June 30, 2026, the largest Autolus Therapeutics plc (AUTL) holders among the 13F filers tracked by SignalX were Blackstone Group ($32.8 million), Renaissance Technologies LLC ($3.2 million), Bank of America Corp ($2.6 million), BlackRock ($2.6 million), Morgan Stanley ($2.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the latest AUTL SEC filings?
Autolus Therapeutics plc (AUTL) filed an 8-K current report on August 11, 2026 and a Form 4 insider filing on September 3, 2026.
What is AUTL's SEC CIK number?
Autolus Therapeutics plc (AUTL)'s SEC Central Index Key (CIK) is 1730463. EDGAR lists every AUTL filing under that number.
Ask anything about AUTL
The research agent reads AUTL's filings, financials, insider trades and 13F holders, then answers with sources.